Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

NCT00390897 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00390897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2003
Completion date
December 31, 2007
Enrollment
360
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukaemia